Konruns(SH:603590) Xin Lang Cai Jing·2025-10-30 02:26Core Insights - 康辰药业 reported a total revenue of 692 million yuan for Q3 2025, ranking 26th among disclosed peers [1] - The net profit attributable to shareholders was 128 million yuan, with a cash inflow from operating activities of approximately 83.9 million yuan, reflecting a year-on-year decrease of 24.90% [1] Financial Performance - The latest asset-liability ratio stands at 13.92%, an increase of 1.88 percentage points from the previous quarter and 1.94 percentage points from the same period last year [3] - The gross profit margin is reported at 90.15%, showing a slight decrease of 0.03 percentage points from the previous quarter [3] - The return on equity (ROE) is recorded at 4.00% [3] Earnings and Ratios - The diluted earnings per share (EPS) is 0.81 yuan [4] - The total asset turnover ratio is 0.17 times, while the inventory turnover ratio is 1.04 times, which is a decrease of 0.22 times or 17.60% year-on-year [4] Shareholder Structure - The number of shareholders is approximately 10,700, with the top ten shareholders holding a total of 89.64 million shares, accounting for 56.25% of the total share capital [4] - The largest shareholder, Liu Jianhua, holds 31.27% of the shares [4]